基于经穴的生物反馈物理调控高血压临床研究

注册号:

Registration number:

ChiCTR2200067147 

最近更新日期:

Date of Last Refreshed on:

2023-06-30 10:13:24 

注册时间:

Date of Registration:

2022-12-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于经穴的生物反馈物理调控高血压临床研究

Public title:

Biofeedback physical regulation of hypertension based on acupoints: a clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于经穴的生物反馈物理调控高血压临床研究

Scientific title:

Biofeedback physical regulation of hypertension based on acupoints: a clinical trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2200006894

申请注册联系人:

马凌慧 

研究负责人:

马良宵 

Applicant:

Ma Linghui 

Study leader:

Ma Liangxiao 

申请注册联系人电话:

Applicant telephone:

+86 13078434035

研究负责人电话:

Study leader's
telephone:

+86 13301188102

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2603306000@qq.com

研究负责人电子邮件:

Study leader's E-mail:

maliangxiao@vip.sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 Beisanhuan Road East, Chaoyang District, Beijing

Study leader's address:

11 Beisanhuan Road East, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学针灸推拿学院

Applicant's institution:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

研究负责人所在单位:

北京中医药大学针灸推拿学院

Affiliation of the Leader:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022BZYLL1207

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京中医药大学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-26 00:00:00

伦理委员会联系人:

李梅、赵丽红

Contact Name of the ethic committee:

Li Mei、Zhao Lihong

伦理委员会联系地址:

北京市朝阳区北三环东路11号

Contact Address of the ethic committee:

11 Beisanhuan Road East, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 53911431

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学

Primary sponsor:

Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市朝阳区北三环东路11号

Primary sponsor's address:

11 Beisanhuan Road East, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

北京中医药大学

具体地址:

北三环东路11号

Institution
hospital:

Beijing University of Chinese Medicine

Address:

11 Beisanhuan Road East

经费或物资来源:

国家重点研发计划(项目编号:2020YFC2007303)

Source(s) of funding:

National Key R&D Program of China (Project Number:2020YFC2007303)

研究疾病:

高血压  

Target disease:

High blood pressure

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察经皮穴位电刺激治疗高血压的疗效及安全性、筛选理想经穴电刺激参数。  

Objectives of Study:

To observe the efficacy and safety of transcutaneous electrical acupoint stimulation(TEAS)in the treatment of hypertension and to screen the optimal stimulation parameters of TEAS.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.继发性高血压患者:如急慢性肾小球肾炎、肾动脉狭窄、妊娠高血压综合征、嗜铬细胞瘤、原发性醛固酮增多症等;
2.具有电刺激仪使用的禁忌症:带有心脏起搏器或其他植入式器械;患有急性病、传染病及其他恶性疾病;处于妊娠或哺乳期;穴位皮肤处有破损、炎症、瘢痕等;感觉障碍或电刺激过敏等;
3.过去一个月曾服用除降压药以外可能影响血压的其他药物,如糖皮质激素等;
4.过去一年曾接受过针灸或经皮电刺激治疗者。

Exclusion criteria:

1. Patients with secondary hypertension: such as acute and chronic glomerulonephritis, renal artery stenosis, gestational hypertensive syndrome, pheochromocytoma, primary aldosteronism, etc.;
2. Contraindications to the use of electrical stimulation devices: with pacemakers or other implantable devices; suffering from acute diseases, infectious diseases and other malignant diseases; in pregnancy or lactation; breakage, inflammation, scarring, etc. at the skin of the acupuncture point; sensory impairment or allergy to electrical stimulation, etc.;
3. Have taken medications other than antihypertensive drugs that may affect blood pressure, such as glucocorticoids, in the past month;
4. Have received acupuncture or transcutaneous electrical stimulation treatment in the past year.

研究实施时间:

Study execute time:

From 2022-12-26 00:00:00 To 2023-12-26 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-28 00:00:00 To 2023-12-26 00:00:00

干预措施:

Interventions:

组别:

经皮穴位电刺激2Hz组

样本量:

40

Group:

TEAS-2Hz

Sample size:

干预措施:

经皮穴位电刺激2Hz + 常规治疗

干预措施代码:

Intervention:

TEAS-2Hz + usual care

Intervention code:

组别:

经皮穴位电刺激10Hz组

样本量:

40

Group:

TEAS-10Hz

Sample size:

干预措施:

经皮穴位电刺激10Hz + 常规治疗

干预措施代码:

Intervention:

TEAS-10Hz + usual care

Intervention code:

组别:

常规治疗组

样本量:

40

Group:

usual care group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

usual care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

朝阳区 

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

北京中医药大学 

单位级别:

三级甲等 

Institution
hospital:

Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

收缩压

指标类型:

主要指标

Outcome:

SBP, systolic blood pressure

Type:

Primary indicator

测量时间点:

治疗后第四周

测量方法:

Measure time point of outcome:

Week 4 after treatment

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

DBP, diastolic blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

HR, heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

HRV, Heart Rate Variability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Morisky服药依从性量表

指标类型:

次要指标

Outcome:

Morisky Medication Adherence Scale, MMAS-8

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命质量调查量表

指标类型:

次要指标

Outcome:

The Standard 12-item Short Form Health Survey (SF-12)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

MAP, mean arterial pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用区组随机法,随机序列由一位专业的统计学家用计算机产生,该统计学家不参与试验评价、治疗或分析。

Randomization Procedure (please state who generates the random number sequence and by what method):

The blocked randomization sequence was prepared by a professional statistician with computer, who is not involved in assessment, treatment or analysis.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对结局评价者和数据统计分析者设盲

Blinding:

Blind method for evaluators and statisticians.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

北京中医药大学

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Beijing University of Chinese Medicine

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

北京中医药大学

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Beijing University of Chinese Medicine

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-12-28 09:21:39